Exciting news from Japan! The Ministry of Health, Labour and Welfare (MHLW) has officially approved Sarepta Therapeutics’ groundbreaking gene therapy for Duchenne muscular dystrophy (DMD). This pivotal decision opens up new horizons for patients in Japan battling this challenging condition, offering hope and enhanced treatment options like never before.